RVL Pharmaceuticals plc Ordinary Shares
RVLP
RVLP was delisted on the 20th of October, 2023.
42 hedge funds and large institutions have $13.6M invested in RVL Pharmaceuticals plc Ordinary Shares in 2019 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
17% more funds holding
Funds holding: 36 → 42 (+6)
8% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 12
37% less capital invested
Capital invested by funds: $21.6M → $13.6M (-$8.01M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$905K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$780K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$132K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$124K |
| 5 |
Renaissance Technologies
New York
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.11M |
| 2 |
DM
Deerfield Management
New York
|
-$3.05M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.91M |
| 4 |
SCM
Sio Capital Management
New York
|
-$1.25M |
| 5 |
BC
Broadfin Capital
New York
|
-$1.11M |
RVLP Hedge Fund Activity: Q2 2019 in Review
42 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q2 2019, worth a combined $13.6M — down 37% from $21.6M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RVLP positions and 5 closed out — a net gain of 7 holders — while 13 added to existing stakes and 12 trimmed.
The largest buyer was Sofinnova Investments, adding an estimated $905K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $3.11M sold.
- 42 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q2 2019, up from 36 in Q1 2019.
- Funds reported $13.6M of RVL Pharmaceuticals plc Ordinary Shares stock for Q2 2019, down 37% quarter-over-quarter.
- 12 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q2 2019 and 5 closed out, a net change of +7 holders.
- The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q2 2019 was Sofinnova Investments, an estimated $905K added.
- The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q2 2019 was Sphera Funds Management, an estimated $3.11M sold.
Based on aggregated 13F filings for Q2 2019.